Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected to show a rise in quarterly revenue when it reports results on August 13 for the period ending June 30 2025
The New York City-based company is expected to report a 17.0% increase in revenue to $1.142 million from $976 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lucid Diagnostics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00, about 66.8% above its last closing price of $1.00
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.16
-0.16
-0.52
Missed
-228.7
Dec. 31 2025
-0.19
-0.18
Beat
5.3
Sep. 30 2024
-0.22
-0.22
-0.25
Missed
-13.6
Jun. 30 2024
-0.22
-0.22
-0.23
Missed
-4.5
Mar. 31 2024
-0.26
-0.27
-0.40
Missed
-49.3
Dec. 31 2023
-0.27
-0.26
-0.25
Beat
3
Sep. 30 2023
-0.27
-0.27
-0.34
Missed
-24.8
Jun. 30 2023
-0.32
-0.32
-0.23
Beat
28.3
This summary was machine generated August 11 at 13:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)